Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan, Chen Qiu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Weiping Yuan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 879.

https://doi.org/10.1182/blood-2023-180351

Published: 2023

Journal Articles

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Jingyu Xu, Wenqiang Yan, Lingna Li, Chenxing Du, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2023-178217

Published: 2023

Journal Articles

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Jingyu Xu, Lingna Li, Wenqiang Yan, Huishou Fan, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 10011–10012.

https://doi.org/10.1182/blood-2022-165889

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Weiwei Sui, Shuhui Deng, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 4371–4373.

https://doi.org/10.1182/blood-2022-157223

Published: 2022

Journal Articles

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Wenqiang Yan, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2021) 138 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2021-149464

Published: 2021

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Lanting Liu, Zhen Yu, MD, Hui Cheng, Weiwei Sui, Shuhui Deng, MD, Xiaojing Wei, Chenxing Du, MD, Wenyang Huang, Gang An, Wen Zhou, PhD, Tao Cheng, Lugui Qiu, MD, Mu Hao

Blood (2020) 136 (Supplement 1): 55.

https://doi.org/10.1182/blood-2020-139006

Published: 2020

Journal Articles

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Xue-Han Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Chenxing Du, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140464

Published: 2020

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Chengwen Li, Shuhua Yi, MD, Mu Hao, Dehui Zou, MD, Fenghuang Zhan, MD PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4343.

https://doi.org/10.1182/blood-2019-129739

Published: 2019

Journal Articles

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Yuting Yan, Yan Xu, Xuehan Mao, MD, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Li Zengjun, Shuhua Yi, MD, Rui Lv, Shuhui Deng, MD, Weiwei Sui, Mu Hao, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Gang An, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4405.

https://doi.org/10.1182/blood-2019-124096

Published: 2019

Journal Articles

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5491.

https://doi.org/10.1182/blood-2019-131730

Published: 2019

NARROW

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only